488 related articles for article (PubMed ID: 17349861)
1. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
Marek GJ
Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
[TBL] [Abstract][Full Text] [Related]
2. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY; Huang M
Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
[TBL] [Abstract][Full Text] [Related]
3. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
4. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
Di Pietro NC; Seamans JK
Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
[TBL] [Abstract][Full Text] [Related]
5. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
[TBL] [Abstract][Full Text] [Related]
6. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.
Jann MW
Pharmacotherapy; 2004 Dec; 24(12):1759-83. PubMed ID: 15585443
[TBL] [Abstract][Full Text] [Related]
7. Alterations of dopamine and serotonin transmission in schizophrenia.
Remington G
Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
[TBL] [Abstract][Full Text] [Related]
8. Serotonin and dopamine interactions in psychosis prevention.
Richtand NM; McNamara RK
Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
[TBL] [Abstract][Full Text] [Related]
9. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
Meltzer HY; Sumiyoshi T
Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
11. Alterations of serotonin transmission in schizophrenia.
Abi-Dargham A
Int Rev Neurobiol; 2007; 78():133-64. PubMed ID: 17349860
[TBL] [Abstract][Full Text] [Related]
12. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
[TBL] [Abstract][Full Text] [Related]
13. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders.
Wood MD; Wren PB
Prog Brain Res; 2008; 172():213-30. PubMed ID: 18772035
[TBL] [Abstract][Full Text] [Related]
14. Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia.
Javanbakht A
Med Hypotheses; 2006; 67(5):1173-84. PubMed ID: 16824690
[TBL] [Abstract][Full Text] [Related]
15. Neurobiology of dopamine in schizophrenia.
Guillin O; Abi-Dargham A; Laruelle M
Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of schizophrenia and the role of newer antipsychotics.
Risch SC
Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
[TBL] [Abstract][Full Text] [Related]
17. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
Nikam SS; Awasthi AK
Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
[TBL] [Abstract][Full Text] [Related]
18. Drugs in development for the treatment of schizophrenia.
Emsley R
Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093
[TBL] [Abstract][Full Text] [Related]
19. [Schizophrenia: a psychobiological view].
RodrÃguez-Arias M; Aguilar MA; Espert R; Miñarro J
Rev Neurol; 1996 Oct; 24(134):1210-20. PubMed ID: 8983716
[TBL] [Abstract][Full Text] [Related]
20. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
